A systematic review of clinical decision support systems for antimicrobial management: are we failing to investigate these interventions appropriately? by Rawson, T. M. et al.
              
City, University of London Institutional Repository
Citation: Rawson, T. M., Moore, L. S. P., Hernandez, B., Charani, E., Castro-Sanchez, E. 
ORCID: 0000-0002-3351-9496, Herrero, P., Hayhoe, B., Hope, W., Georgiou, P. and 
Holmes, A. H. (2017). A systematic review of clinical decision support systems for 
antimicrobial management: are we failing to investigate these interventions appropriately?. 
Clinical Microbiology and Infection, 23(8), pp. 524-532. doi: 10.1016/j.cmi.2017.02.028 
This is the published version of the paper. 
This version of the publication may differ from the final published 
version. 
Permanent repository link:  https://openaccess.city.ac.uk/id/eprint/24430/
Link to published version: http://dx.doi.org/10.1016/j.cmi.2017.02.028
Copyright and reuse: City Research Online aims to make research 
outputs of City, University of London available to a wider audience. 
Copyright and Moral Rights remain with the author(s) and/or copyright 
holders. URLs from City Research Online may be freely distributed and 
linked to.
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
City Research Online
lable at ScienceDirect
Clinical Microbiology and Infection 23 (2017) 524e532Contents lists avaiClinical Microbiology and Infection
journal homepage: www.cl in icalmicrobiologyandinfect ion.comSystematic reviewA systematic review of clinical decision support systems for
antimicrobial management: are we failing to investigate these
interventions appropriately?
T.M. Rawson 1, *, L.S.P. Moore 1, B. Hernandez 2, E. Charani 1, E. Castro-Sanchez 1,
P. Herrero 2, B. Hayhoe 3, W. Hope 4, P. Georgiou 2, A.H. Holmes 1
1) National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance,
Imperial College, London, UK
2) Department of Electrical and Electronic Engineering, Imperial College, London, UK
3) School of Public Health, Imperial College, London, UK
4) Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UKa r t i c l e i n f o
Article history:
Received 17 November 2016
Received in revised form
23 February 2017
Accepted 25 February 2017
Available online 6 March 2017
Editor: Mical Paul
Keywords:
Antimicrobial resistance
Antimicrobial stewardship
Decision algorithms
Electronic support* Corresponding author: T.M. Rawson, National I
Health Protection Research Unit in Healthcare
Antimicrobial Resistance, Imperial College London,
Cane Road, London, W12 0NN, UK.
E-mail address: timothy.rawson07@ic.ac.uk (T.M. R
http://dx.doi.org/10.1016/j.cmi.2017.02.028
1198-743X/© 2017 The Authors. Published by Elsevier
the CC BY-NC-ND license (http://creativecommons.ora b s t r a c t
Objectives: Clinical decision support systems (CDSS) for antimicrobial management can support clini-
cians to optimize antimicrobial therapy. We reviewed all original literature (qualitative and quantitative)
to understand the current scope of CDSS for antimicrobial management and analyse existing methods
used to evaluate and report such systems.
Method: PRISMA guidelines were followed. Medline, EMBASE, HMIC Health and Management and Global
Health databases were searched from 1 January 1980 to 31 October 2015. All primary research studies
describing CDSS for antimicrobial management in adults in primary or secondary care were included. For
qualitative studies, thematic synthesis was performed. Quality was assessed using Integrated quality
Criteria for the Review Of Multiple Study designs (ICROMS) criteria. CDSS reporting was assessed against
a reporting framework for behaviour change intervention implementation.
Results: Fifty-eight original articles were included describing 38 independent CDSS. The majority of
systems target antimicrobial prescribing (29/38;76%), are platforms integrated with electronic medical
records (28/38;74%), and have a rules-based infrastructure providing decision support (29/38;76%). On
evaluation against the intervention reporting framework, CDSS studies fail to report consideration of the
non-expert, end-user workflow. They have narrow focus, such as antimicrobial selection, and use proxy
outcome measures. Engagement with CDSS by clinicians was poor.
Conclusion: Greater consideration of the factors that drive non-expert decision making must be
considered when designing CDSS interventions. Future work must aim to expand CDSS beyond simply
selecting appropriate antimicrobials with clear and systematic reporting frameworks for CDSS in-
terventions developed to address current gaps identified in the reporting of evidence. T.M. Rawson, Clin
Microbiol Infect 2017;23:524
© 2017 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In response to the global threat of antimicrobial resistance [1], a
range of antimicrobial stewardship programmes have beennstitute for Health Research
Associated Infections and
Hammersmith Campus, Du
awson).
Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).developed that tend to focus on reducing high rates of inappro-
priate antimicrobial use described widely across care pathways and
clinical specialties [2e5]. An important facet of this approach has
been the development of decision support mechanisms for those
who prescribe antimicrobials. These interventions are based on
evidence that the majority of antimicrobial prescribing is done by
individuals who are not experts in infection management and
therefore, may have a limited understanding of antimicrobials and
the evidence on antimicrobial resistance [6e9]. To address this
challenge, electronic clinical decision support systems (CDSS) haveof Clinical Microbiology and Infectious Diseases. This is an open access article under
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and rapid access to information, which is required to make thera-
peutic decisions at the point-of-prescription [10,11]. With the
expanding use of electronic medical records and developments in
information technology, the role of CDSS has become an area of
great interest with a wide variety of interventions now labelled as
such.
In medicine, CDSS have been demonstrated to reduce medical
errors and improve the quality of health care provided by pro-
moting the practice of evidence-based medicine [12]. Therefore, it
seems logical that in a field where we have a need to improve the
practice of evidence-based antimicrobial management CDSS may
be an effective avenue to promote this. CDSS were first developed
to support antimicrobial management in the 1980s and since then
several systematic reviews of experimental and quasi-experimental
studies have explored the potential of CDSS to improve antimi-
crobial management at different levels of care [11,13,14]. However,
these reviews have only tended to focus on single care pathways,
such as the hospital setting or primary care and fail to include
qualitative studies evaluating CDSS. Through these reviews, a mi-
nor to moderate benefit of CDSS for optimizing antimicrobial
management has been demonstrated with a number of gaps in
knowledge remaining to be answered [11,13,14]. We performed a
systematic review of original literature (qualitative and quantita-
tive) to try to understand the current scope of CDSS for antimi-
crobial management and analyse existingmethods used to evaluate
and report such systems. This will be used to create a pragmatic
picture of CDSS for antimicrobial management and produce rec-
ommendations for future research and interventions, which may
optimize the effectiveness of CDSS reporting within this field.
Materials and method
Search strategy
This systematic review was performed following PRISMA
guidelines [15]. The Medline, EMBASE, HMIC Health and Manage-
ment, and Global Health databases were searched from 1 January
1980 to 31 October 2015 using the search criteria described in the
Supplementary material (Table S1). Search criteria were broad and
intended to capture all information technology products that have
been labelled as ‘clinical decision support systems’ for antimicro-
bial management.
Study selection
Prospective and retrospective articles in English that reported
original research on clinical patient or product outcomes of CDSS
for antimicrobial management in primary and secondary carewereTable 1
Analytical framework for the assessment of clinical decision support systems applied to
Domain 1: Development Domain 2: Feasibility and Piloting
Literature describing a system
should demonstrate:
A definition of stakeholder
behaviours that are being
targeted and how stakeholders
have been engaged with during
the development phase
A rationale for how the intervention
may influence these behaviours
An outline of how the system was
developed
Literature describing a system
should outline:
How pilot testing was performed
and the findings of this
An understanding of the
mechanism of behaviour change
witnessed and how the
intervention may be having its
effect
Analytical framework adapted from Stage Model of Behaviour Intervention Developmen
terventions guidance [23].included. Randomized (including cluster), observational
(including caseecontrol, cross-sectional, cohort, beforeeafter and
interrupted time series), diagnostic, development reports
(including data), mixed-methods, and qualitative (survey, semi-
structured interview or ethnographic) studies were all included.
Interventions focusing predominantly on critical care were
excluded as these CDSS are often used by doctors in a controlled
setting, where close working relationships with infection spe-
cialists have been demonstrated to significantly improve patient
outcomes [16e20]. Therefore, these CDSS interventions may not
be used in a similar way to other areas, where they are often used
to supplement this expert support. Moreover, CDSS designed
specifically for paediatric antimicrobial management were
excluded given the differences in prescribing compared with adult
antimicrobial management. If studies did not present original data,
they were not carried forward. Two authors (TMR plus either
LSPM, EC or ECS) independently screened study titles and abstracts
against the inclusion and exclusion criteria described above and
extracted data (described below). On completion of this process,
inter-rater reliability was assessed by calculating Cohen’s k sta-
tistic. Where there was disparity between opinions, the authors
discussed these to reach a consensus.
Decision support system grouping and data extraction
Following study selection, two authors (TMR plus either LSPM,
EC or ECS) independently reviewed each study, grouping those for
each CDSS described and extracting data. Data recorded included
the characteristics of the CDSS (decision support provided, plat-
form, and system infrastructure), the study design(s) used to
evaluate the CDSS, and any comparator used. Primary and sec-
ondary outcomes were recorded when presented in the manu-
script, as was the outcome of these. Qualitative studies were
analysed using a thematic synthesis approach [21]. Qualitative
studies were synthesized using an inductive approach with line by
line coding of the text to draw out descriptive themes (carried out
by one author, TMR). Manuscripts were then re-coded and dis-
cussed by the researchers (TMR, LSPM, EC, ECS) to agree upon
analytical themes from within the text [21]. Finally, the CDSS sys-
tems were evaluated against an analytical framework adapted from
the Stage Model of Behaviour Intervention Development [22] and
the Medical Research Council’s Developing and Evaluating complex
interventions guidance [23]. The framework is outlined in Table 1.
The four domains of the framework used to evaluate the CDSS were
(a) development; (b) feasibility and piloting; (c) evaluation of the
system; and (d) implementation. When included within reporting
of such systems these criteria will allow the reader to understand
holistically the rationale for why and how a CDSS was developed
and how its effectiveness was evaluated [22,23].the studies in this review
Domain 3: Evaluation Domain 4: Implementation
Literature describing a system
should demonstrate:
Efficacy testing in a ‘real-world’
setting
High levels of control maintained to
confirm internal validity of
intervention
Confirm how the intervention
changes practice and quantify its
impact
Literature describing a system
should outline:
How it was tested in the real
world with real-world providers
Strategies for implementation and
adoption of intervention that
were used and how these may
have impacted on observations
Plans for (or evidence of) long-term
surveillance / follow up of the
system
t [22] and the Medical Research Council’s Developing and Evaluating complex in-
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Given the heterogeneity of studies included within this review,
we opted to use the Integrated quality Criteria for the Review Of
Multiple Study designs (ICROMS) criteria [24]. ICROMS aims to
facilitate the review of behaviour change interventions in the field
of infection, such as clinical decision support tools. It facilitates the
review of multiple study designs that include randomized control
trials (RCTs) (including cluster-RCTs), cohort, beforeeafter and
interrupted time series studies, as well as qualitative studies [24].
For studies that were not included in ICROMS, we quality assessed
these using validated criteria from the literature. These were the
Strengthening the Reporting of Observational Studies in Epidemi-
ology (STROBE) criteria for cross-sectional studies and caseecontrol
studies [25]; the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) criteria for economic evaluations
[26]; and the Standards for Reporting Diagnostic Accuracy Studies
(STARD) criteria for diagnostic studies [27]. For development re-
ports, we were unable to assign a quality criterion (and these were
therefore labelled as high risk of bias).
Using these quality criteria, studies were scored as advised
within ICROMS [24]. A study was awarded 2 points if a specific
criterion was met, 0 points if the criterion was not met, and 1 point
if it was unclear. The sum of the quality criterion was then given to
represent a global quality score for each study. Based on recom-
mendations from ICROMS scores <60% of the maximum attainable
score for that criterion were labelled high risk of bias / low reli-
ability (defined ‘high risk’) [24]. Scores of 60%e80% of the total for
that study type were labelled medium risk of bias / medium reli-
ability (‘medium risk’) and studies with >80% of the total score for
that study type were labelled low risk of bias / high reliability (‘low
risk’). Given that our objectives were to capture all relevant litera-
ture, we did not exclude data based on the quality of evidence
provided.
Summary measures
Following extraction and synthesis, data were reviewed by all
researchers to identify current barriers and facilitators to success in
practice. All major primary outcomemeasures described within the
studies were grouped and classified into either patient level, pre-
scriber level or unit/hospital level outcomes. These were tabulated
and the level of evidence for overall achievement of each primary
outcome demonstrated within the literature for these groups was
graded using Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) criteria [28].
Results
Study selection and characteristics
Fig. 1 describes the screening and eligibility checking process
that was undertaken. An initial electronic search identified 402
individual titles and abstracts for screening. Of these, 131/402
(33%) abstracts were carried forward for eligibility screening and
58/131 (44%) were included in the review. Cohen’s k for agree-
ment was 0.88. These 58 studies described 38 different CDSS.
Table 2 summarizes the attributes of the CDSS identified. Sup-
plementary material (Table S2) outlines the full evaluation of the
38 CDSS. On assessment of the risk of bias of included studies
using ICROMS, the majority of studies in primary care were found
to be low to medium risk (7/18; 39% and 8/18; 44%, respectively),
whereas the majority of studies reported from secondary care
were medium to high risk (15/40; 38% and 22/40; 55%, respec-
tively) of bias.Decision support systems reported in the literature
The majority of CDSS in the literature target antimicrobial pre-
scribing (29/38; 76%). The 11 systems focused on antimicrobial
prescribing in primary care provided decision support for specific
syndromic presentation in adults. The conditions targeted were
acute respiratory tract infections (ARIs), with two CDSS also
including urinary tract infections (UTIs) [29e46]. In contrast, sys-
tems supporting antimicrobial prescribing in secondary care tar-
geted broader populations with interventions tending to focus on
empirical and prophylactic antimicrobial prescribing rather than
individual syndromes (exceptions included pneumonia, UTI,
methicillin-resistant Staphylococcus aureus, Clostridium difficile
infection) [47e85,95]. Other decision support provided by CDSS for
antimicrobial management included electronic prompts/alerts (7/
38; 18%); optimizing antimicrobial dosing (3/38; 8%); supporting
antimicrobial de-escalation (2/38; 5%); surveillance (2/38; 5%); and
prescriber feedback (1/38; 3%).
Several platforms for delivering CDSS were reported, including
systems being integrated into hospital electronic medical record
(28/38; 74%), via web-based platforms (5/38; 13%), via personal
digital assistants (3/38; 9%), and as stand-alone software (2/38; 5%).
The reported infrastructure providing decision support was pre-
dominantly rules based (29/38; 76%). There were also a number of
machine learning tools reported including; use of neural networks
(2/38; 5%), association rule learning algorithms (1/38; 3%) and
predictive models (1/38; 3%). These were all reported in secondary
care.
Analysis of CDSS development & pilot and feasibility testing
domains
On comparison with domains 1 and 2 of our defined analytical
framework (Table 1), a paucity of evidence exists to describe stake-
holder involvement in the development processes for CDSS. This
includes a lack of evidence supporting pre-intervention stakeholder
analysis, evidence exploring user decision processes, and how in-
terventions will fit into routine clinical workflow. For example,
Andreassen et al. describe the development of an intelligent CDSS
using Causal Probabilistic Networks (TREAT) for use in secondary
care [67]. Within this report, much detail is placed on the construc-
tion of a pathophysiological model for the diagnosis of infection and
antimicrobial selection. However, no evidence is provided to
describe prescriber’s decision pathways and how the system will
integrate into this process in clinical practice. In contrast,McDermott
et al. report during the development of the eCRT study engagement
with a small number of stakeholders (n¼ 33) in the design of the
intervention based on behaviour change theories [42,94]. However,
post-implementation review of this intervention identified prob-
lems with variations in individuals prescribing behaviours, lack of
end-user engagement with implementation, and rigidity of the
guidelines incorporated limiting the use of the system [40]. These
aspects of the clinician’s decision-making processwere not explored
during the development phase. This observation is supported by
Zaidi et al., who highlighted workflow-related issues of their CDSS
with junior medical staff during the post-intervention qualitative
evaluation of their product [79].
Analysis of evidence domain
For analysis of framework domain 3, examination of experi-
mental design studies in primary care reveals primary outcome
measures were heterogeneous and tended to focus on the rates of
prescribing of antibiotics either overall or for a defined syndrome.
These studies demonstrated zero to minor clinically significant
Table 2
Summary of clinical decision support systems evaluated
CDSS characteristics n (%)
System setting
Primary care 11 (29)
Secondary care 27 (71)
Types of decision support
Antibiotic prescribing 29 (76)
Physician feedback 1 (3)
Alerts / prompts 7 (18)
Dose optimization 3 (8)
De-escalation 2 (5)
Surveillance 2 (5)
CDSS Platform
Integrated into EMR 28 (74)
On PDA device 3 (8)
Web-based application 5 (13)
Stand-alone software 2 (5)
System Attributes
Rule baseda 29 (76)
Causal probabilistic networks 1 (3)
Drug-bug logic 1 (3)
Pharmacokinetic modellinga 2 (5)
Fuzzy cognitive mapping 1 (3)
Guidelines 2 (5)
Predictive models 1 (3)
N/A 2 (5)
Abbreviations: CDSS, clinical decision support systems; EMR, electronic
medical records; N/A, not avilable; PDA, personal digitl assistant.
a One system had multiple attributes.
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Fig 1. PRISMA flow diagram outlining study selection for inclusion within the systematic review of clinical decision support for infection management in primary and secondary
care.
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demonstrating primary outcome measures were often reported as
being due to the intention-to-treat analysis, with poor uptake of
the CDSS intervention by clinicians cited as the major driver for
this [30,41]. For example, Linder et al., reported a cluster-RCT
investigating the use of a rule-based (guideline-driven) CDSS
embedded in a primary care practice’s electronic medical records
for antimicrobial prescribing in ARIs [32]. During the intervention
period of the study 21 961 visits were made by patients with ARIs.
A total of 11 954 visits were in primary care clinics where the CDSS
had been implemented. Of these visits, the CDSS intervention was
only used 6% of the time [31]. The study did not demonstrate
improvement in reducing overall rates of prescribing for ARI visits
(43% in control versus 39% in intervention (OR 0.8, 95% CI 0.6e1.2).
In experimental interventions where primary outcomes were met,
such as the RCT reported by McGinn et al. testing the Clinical
Prediction Rules CDSS, outcomes focused on a rules-based system
designed for specific types of ARI and demonstrated a 10%
reduction in antimicrobial prescribing for these conditions
(adjusted RR 0.74, 95% CI 0.60e0.92) [39]. However, clinical out-
comes and unintended consequences of reducing antimicrobial
prescribing for this cohort were not investigated. CDSS adoption
rates in this study were reported as 62.8% [39]. Therefore, there is
a large variation in uptake of such interventions between studies,
which appears to influence the achievement of clinical and sta-
tistical outcomes.
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reporting CDSS evaluation. These evaluated two systems. Again,
outcome measures were extremely variable, making comparison
between interventions difficult. One trial, reported by McGregor
et al. described an electronic alert system for antimicrobial man-
agement teams demonstrated a significant financial benefit, with
the trial stopped early after the authors demonstrated savings of
over $84,000 during a 3-month study period where the interven-
tion was used on 359 patients versus 180 controls [80]. The
remaining two experimental studies reported did not show sig-
nificant improvements in primary outcomes following adjustment.
These studies both used a CDSS incorporating Causal-Probabilistic
Networks (TREAT). Primary outcome measures were the appro-
priateness of empirical prescribing and 180-day survival following
treatment, respectively [69,71]. Where primary outcome looked at
the appropriateness of empirical therapy compared with detected
organism sensitivity, TREAT did demonstrate a 9% improvement in
appropriateness of prescribing [69]. However, once findings were
adjusted for medical ward clustering and site, using multivariate
regression, the findings did not reach significance (OR 1.48, 95% CI
0.95e2.29). This may have been partly due to under-powering of
the study, due to financial and time constraints, cited by the authors
[69]. Furthermore, in the second trial assessing 180-day survival,
failures were once again in the intention-to-treat analysis, with
significant benefits identified on per-protocol analysis (6% increase
in survival, p 0.04), suggesting that clinical uptake of interventions
may once again be a contributing factor, along with appropriate
powering of cluster-RCTs [71].
Analysis of implementation and prescriber engagement with
systems
On analysis of framework domain 4, we identified that many of
the CDSS interventions investigated in experimental studies failed
in the intention-to-treat analysis, with poor physician uptake of the
intervention appearing to be a contributing factor. This finding is
supported on review of published qualitative studies investigatingTable 3
Primary outcome measures identified from systematic review of the literature of clinical
Primary outcome measure Total number
Unit level
Disease specific antimicrobial prescribing rate
(e.g. in total ARI visits)
6
Rate of antimicrobial prescribing (e.g. DDD/
1000 patient bed days)
3
Economic benefit of CDSS 3
Patient level
Mortality (e.g. 30 and 180 days) 1
Patient specific complications (SSIs / ADEs /
HCAI)
1
Diagnostic accuracy e.g. Infection type (e.g. ARI /
UTI), Predicting probability of bloodstream
infection, or predict causative organism
3
Individualized dose optimization 1
Prescriber level
Appropriate empirical prescribingdagainst
subsequent bug sensitivity
3
Individual changes in prescribing behaviour
(including de-escalation)
4
Adherence to local guidelines 9
Appropriate prescribingdduration / timing of
therapy
2
Acceptance of CDSS 2
Compliance with dosing guidance 2
Abbreviations: ADE, adverse drug event; ARI, acute respiratory tract infection; CDI, Cl
infection; SSI, skin and soft-tissue infection; UTI, urinary tract infection.
a H, high quality; M, medium quality; L, low quality.CDSS implementation in both primary and secondary care. Here, a
common theme emerges describing barriers to physician engage-
ment with such systems. In primary care, a number of patient,
physician and technical aspects causing a lack of engagement with
interventions were identified by Litvin et al. and McDermott et al.
[34,40]. For example, both studies cite technical aspects, like us-
ability and work flow of the intervention in normal clinical practice
as potential barriers to use, especially when it was felt to reduce
time with or detract from engagement with the patient [34,40].
Moreover, physician factors such as perceived level of clinical
experience and agreement with conventional CDSS were cited as
factors that influenced engagement with the intervention; physi-
cian engagement was similarly found to be an issue by Zaidi et al.,
who assessed the implementation of a CDSS in an Australian hos-
pital [78,79]. However, of note was the paucity of information
available describing mechanisms to support implementation and
adoption of CDSS as well as a lack of stakeholder follow up and
long-term surveillance of interventions to support such
observations.
Review of reported primary outcome measures of CDSS
Major primary outcome measures identified in this review are
outlined in Table 3. Outcome measures were classified based on
demonstration of results at the hospital/unit, patient, or prescriber
level. Evidence was rated as medium to high at supporting the
benefit of CDSS at the hospital and prescriber level, but was poor to
support the impact of CDSS on patient level outcomes, including
mortality and experience of complications. As discussed above,
outcomemeasures tended to be proxy indicators of success, such as
appropriateness compared with guidelines or rates of prescribing.
They often failed to investigate direct patient outcomes from
implementation of CDSS.
Overall, evidence is low to medium for the majority of clinical
outcomes. However, there is high-quality evidence supporting
CDSS at a unit/healthcare organization level to reduce the cost of
antimicrobial therapy, as supported by the RCT reported bydecision support systems for infection management in primary and secondary care
Number achieving outcome Quality of evidencea
3 H
3 M
1 M
1 L
1 L
3 L
1 L
3 H
4 M
7 M
2 M
1 L
0 -
ostridium difficile infection; DDD, daily defined doses; HCAI, healthcare-associated
T.M. Rawson et al. / Clinical Microbiology and Infection 23 (2017) 524e532 529McGregor et al. in secondary care [80]. At the prescriber level, high
quality evidence is available to suggest that CDSS have the potential
to directly influence individual prescribing behaviours. For
example, McGinn et al. reported an RCTwhich implemented clinical
decision algorithms within a primary care electronic medical re-
cord system. This demonstrated significant reductions in antimi-
crobial prescribing and investigations ordered at the individual
physician level [39]. However, there remains a paucity of high-
quality evidence for patient specific outcome measures, such as
mortality or complications of treatment selection, such as adverse
drug events, healthcare-associated infections and other unintended
consequences. This type of evidence is probably not currently
available due to the need for longitudinal follow up of individuals
across complex care pathways and difficulties with powering such
studies.
Discussion
Within this review of CDSS for antimicrobial management of
adults in primary and secondary care, we have identified a het-
erogeneous and disjointed approach to investigating and reporting
CDSS interventions. This has included a paucity of supporting in-
formation to justify the development and deployment of many
CDSS interventions reported, variable study designs, outcome
measures that tend to be of low quality, and a lack of consideration
of supportive measures required to promote prescriber engage-
ment and use of these interventions, such as audit and feedback
during implementation.
Although many of the CDSS interventions reported within this
study are based on decision pathways or guidelines, very few in-
terventions report pre-deployment stake-holder analysis or pre-
scriber decision mapping to justify intervention design. With many
devices built based on expert infection opinion, developers may be
missing a valuable opportunity to explore and understand how
non-expert prescribers’ decision pathways differ when prescribing
antimicrobial therapy. A deeper understanding of these aspects
would allow for more individualized design of interventions to
target specific steps in the prescriber’s workflow as well as justi-
fying development of specific user interface designs. Moreover, a
greater understanding of the challenges within the routine pre-
scriber’s workflow may provider greater insight into other aspects
of decision support that would warrant inclusion with CDSS for
antimicrobial management. These may include specific dose opti-
mization platforms, patient engagement tools or surveillance
modules. This has been supported by several technical reports
analysing key lessons in developing future clinical decision support
systems with pre-deployment stakeholder engagement being re-
ported to provide justification for defining the goals and clinical
objectives of the device, allowing critical consideration of individ-
ual workflow, and facilitating communication across the environ-
ments where they are going to be deployed [86e88].
Second, current study design and outcome reporting require
addressing to promote a standardized view of CDSS. Current in-
vestigations of CDSS for antimicrobial management primarily
involve the selection of heterogeneous, non-standardized, proxy
outcome measures, such as total amounts of antimicrobial pre-
scribing or what is determined ‘appropriate’ antimicrobial pre-
scribing. In primary care, primary outcomes focused on the rate of
antimicrobial prescribing for the syndrome being investigated,
namely ARI. Several different measures of prescribing were used
but these often revolved around total number of prescriptions, not
taking into account the nature of the presentation and other factors
that may have influenced the physician’s decision, such as delayed
prescribing. In secondary care, many studies focused on whether
the antimicrobial prescribed was ‘appropriate’, based on localguidelines, expert opinion, or identified organism sensitivities. As
proxy measures, these outcomes do not directly measure clinical
benefit to the individual or society, such as mortality, adverse
events and development of antimicrobial resistance; many of
which would require longitudinal follow up of individuals across
healthcare pathways. Although addressed as secondary outcomes
in several studies, these tended to be part of subgroup analysis
where minor significance may be demonstrated but no statistical
correction was described in the methodology, such as the Bonfer-
roni correction. Therefore, the rigor of these results cannot be fully
assessed. Future investigators of CDSS for antimicrobial manage-
ment need to ensure that clear outcome measures that are suffi-
ciently powered to demonstrate direct benefit for patients,
prescribers, or healthcare organizations. This may mean that there
is a need for larger, multi-centred collaborations to be set up to
facilitate appropriate sample sizes.
With the growing need to promote cross-specialty engagement
and the joining up of care pathways between primary and sec-
ondary care, a more appropriate way of comparing CDSS may be
through analysis of different intervention types. Studies in primary
care currently fail to assess the effect of changes in prescribing on
secondary care, where patients who fail antimicrobial therapy in
the community may subsequently present to hospital; similarly,
studies based in secondary care may fail to investigate the unin-
tended consequences of actions in hospital on patients discharged
to primary care services. Indeed, much of the impact of changes in
prescribing in both primary and secondary care may currently be
missed by failing to look across the entire patient care pathway.
Yong et al., investigated the impact of a hospital-wide decision
support system to restrict the use of broad-spectrum antimicrobials
on rates of antimicrobial resistance in their intensive care unit,
observing that despite antimicrobial prescribing levels remaining
stable in the intensive care unit, there was an increase in suscep-
tibility of Gram-negative organisms to broad-spectrum agents [89].
This would suggest that prescribing behaviours in another area of
the patient pathway, where significant decreases in prescribing
were described, may have influenced the observed changes in
antimicrobial resistance upstream from the setting. These findings
would support the requirement for longitudinal follow up of in-
dividuals receiving antimicrobials and the need for combining of
primary and secondary care interventions to truly assess the impact
of CDSS at a societal level.
Finally, the role of CDSS on its own is unlikely to be of signif-
icant clinical benefit, requiring synergistic interventions to be
implemented in support of it. Given the current lack of evidence to
support CDSS implementation in non-expert prescribers’ work
flow and the significant lack of engagement with CDSS in-
terventions reported within the literature it is likely that imple-
mentation with education, regular feedback on device use, and
other antimicrobial stewardship-related interventions will be
required to generate interest and use of any CDSS. Therefore, study
design must consider these facets and account for them to allow
interventions to be assessed both separately and as multi-modal
interventions, as is more likely to be the case in clinical practice.
This would further be supported by the development of a suitable
reporting framework to guide the reporting of CDSS intervention
studies, similar to the outbreak reports and intervention studies
for non-interventional trials (ORION) guidelines for healthcare-
associated infection reporting [90]. These guidelines have helped
to raise the standards of research and publication in hospital
epidemiology through setting standards for design and reporting
of studies, allowing for greater generalizability of findings re-
ported in studies [90].
Although several of the challenges described above are not
unique to CDSS for antimicrobial prescribing, we support the
T.M. Rawson et al. / Clinical Microbiology and Infection 23 (2017) 524e532530conclusions drawn by Eichner and Das [91]. Within their review of
the barriers in development and implementation of a CDSS, they
call for specific implementation and evaluation tools for CDSS
within specific fields to promote better integrationwithin end-user
workflow and uptake on implementation [91]. For the role of CDSS
in antimicrobial management we propose that the summary of key
components for reporting CDSS that have been identified within
this review should be considered when developing and reporting
CDSS for antimicrobial management (Table 4). These focus on (a) a
clear description of the system’s technical attributes; (b) consid-
eration and reporting of all four domains of the analytical frame-
work that we have developed for assessing the implementation of
these complex interventions for antimicrobial prescribing; and (c)
clear justification of rationale for the study design used to evaluate
the CDSS, including consideration of outcome measures used to
demonstrate effectiveness.Table 4
Recommended reporting criteria for consideration when describing and evaluating
clinical decision support systems for antimicrobial management
Criteria / Sub-heading Comment
Description of Decision Support Tool
Type of decision support
provided
e.g. Antibiotic prescribing
Dose optimization
Feedback
Surveillance
Platform onwhich it is provided e.g. Integrated into EMR
Web-based
Stand-alone software
Infrastructure e.g. Rule-based
Machine learning
(with description)
System development
Rationale for development e.g. Were stakeholders involved
in defining a need and
developing the tool? How?
Theory behind the intervention
clearly outlined
Clear working hypothesis
Previous feasibility / pilot
testing
e.g. Pilot testing supporting
intervention
Pilot test of how system will
change behaviour
Evidence supporting evaluation e.g. Justify the setting in which
the evaluation is undertaken
Howwill the authors control for
bias?
How the tool is implemented e.g. What support measures
was the tool implemented with
to promote adoption (e.g.
education/training sessions,
audit and feedback)
Study design
Justification for study design e.g. What is the study design?
Why was this selected?
How are confounding factors
controlled for (change in
guidelines, Hawthorne effect,
the effect of implementation
strategies for adoption)?
Outcome measure selection e.g. What is the primary
outcome for this study (patient
outcomes, change in prescriber
behaviour, economic
evaluation)?
Are direct or proxy measures
being used?
Are the unintended
consequences of this
intervention considered?
Will stakeholders be involved
(qualitative evaluation)
EMR, electronic medical records.There were several potential limitations to this study. For
example, the use of cluster-RCT design for experimental studies
does not allow individualization of data, therefore meta-analysis of
interventions is difficult to perform. Second, many CDSS in-
terventions are implemented with a number of other antimicrobial
stewardship-based interventions, such as educational sessions and
prescriber feedback [92,93]. In many cases, it is challenging to
dissect the individual merits of each of these facets of the overall
intervention, making the direct impact of the CDSS more chal-
lenging to determine. Finally, although broad-based search terms
were used to try and capture a broad representation of appropriate
studies, some may have been missed. This includes commercially
developed products that are not reported within the literature and
were not within the scope of this review. Our methodology
included hand searching of reference lists of identified studies to
address this.
In conclusion, CDSS for antimicrobial management currently
demonstrate a potential to facilitate improved evidence-based
antimicrobial use in adults. However, several key areas must be
addressed if the true potential of CDSS in this field is to be effec-
tively explored. CDSS must not be viewed as a magic bullet and as
such, interventions must be multi-modal so that potential syner-
gistic effects can be explored to ensure that interventions are used.
This requires careful consideration of appropriate study design and
the clear and transparent reporting of CDSS interventions with a
focus on demonstrating direct patient impact and surveillance for
unintended consequences of such interventions. The development
of an evidence-based reporting framework for CDSS for antimi-
crobial management would greatly enhance the quality of evidence
available to support such interventions. Furthermore, research
must explore broader integration of different CDSS such as linking
antimicrobial selection with other modules, like dose optimization,
patient engagement tools and automated surveillancemechanisms.
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